La vendita allo scoperto per Travere Therapeutics dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Travere Therapeutics. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Travere Therapeutics (NASDAQ:TVTX) Azioni, Report sulle vendite allo scoperto

Travere Therapeutics

Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN) - rare kidney disorders that often cause end-stage kidney disease.

Travere Therapeutics, Inc. - Common Stock

Travere Therapeutics Inc

<a href="https://www.axios.com/2024/09/27/israel-airstrike-hezbollah-hq-beirut">https://www.axios.com/2024/09/27/israel-airstrike-hezbollah-hq-beirut</a>
&nbsp;
Israel conducted an air strike on Friday targeting <a href="https://www.axios.com/2023/10/27/hezbollah-israel-hamas-war-invasion-gaza-iran">Hezbollah's</a> central headquarters in Beirut in an apparent attempt to kill the group's leadership.
Why it matters: This was the biggest Israeli strike in Beirut since the 2006 war in <a href="https://www.axios.com/2024/09/23/us-israel-lebanon-american-citizens-safety-evacuation">Lebanon</a>, and an Israeli source said the primary target was Hezbollah leader Hassan Nasrallah. The strike also reportedly hit residential buildings, though there has been no word yet on civilian casualties.
Driving the news: Israeli officials say senior Hezbollah officials were at the headquarters at the time of the attack. There has been no official response as yet from Hezbollah on the attack or on Nasrallah's status.
<ul>
<li>Hezbollah-affiliated al-Manar Television reported that four buildings in southern Beirut were hit in the attack.</li>
<li>Israel Defense Forces spokesperson Adm. Daniel Hagari described the attack as a "precise strike on the central HQ of Hezbollah which was intentionally built under residential buildings in Beirut in order to use them as human shields."</li>
<li>Israeli Prime Minister Benjamin <a href="https://www.axios.com/2024/09/27/netanyahu-lebanon-ceasefire-walks-back-comments">Netanyahu</a> abruptly left a press briefing at the UN after receiving an update from his military adviser.</li>
</ul>

Macro Economic Events

News

Global

Economics

iShares MSCI Israel Capped Investable Market Index Fund

ISRA

'Israel Conducts Massive Strike Targeting Hezbollah HQ In Beirut' - Axios

Friday, the FDA lifted the clinical hold on Biomea Fusion, Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMEA#NASDAQ">BMEA</a>) ongoing Phase 1/2 clinical trials of the company&#8217;s investigational covalent menin inhibitor BMF-219 in type 2 and type 1 diabetes (COVALENT-111 and COVALENT-112), <a target="_blank" href="https://www.benzinga.com/pressreleases/24/09/g41053782/fda-lifts-clinical-hold-on-bmf-219-in-type-2-and-type-1-diabetes-trials" rel="noreferrer noopener">respectively</a>.
&#8220;The in-depth review of the clinical data to date reconfirms our confidence in BMF-219 as a novel, first-in-class agent for the treatment of diabetes,&#8221; stated Thomas Butler, Biomea Fusion&#8217;s CEO and Chairman.
&#8220;We are encouraged from the safety review of the ongoing Phase 2b Expansion Study, where the concerning safety signals seen in the Phase 2a Escalation Study did not translate over to the larger Expansion Study. And most importantly, none of the elevated lab values translated to confirmed serious liver injury or liver impairment,&#8221; Butler said.
In June, the FDA placed a clinical hold on Biomea Fusion&#8217;s Phase 1/2 <a target="_blank" href="https://www.benzinga.com/general/biotech/24/06/39223256/this-pharma-stock-dropped-60-premarket-as-fda-halted-diabetes-drug-trials" rel="noreferrer noopener">trials for BMF-219</a>.
The FDA&#8217;s decision was driven by concerns over potential drug-induced hepatotoxicity observed during the Dose Escalation Phase of the trials. Elevated liver enzyme levels were noted, although most adverse events were mild to moderate, with no severe reactions reported.
During its second-quarter earnings release, the company said data readout from COVALENT-111 Phase 2b and COVALENT-112 Phase 2a trials were on track for the <a href="https://www.benzinga.com/pressreleases/24/07/g40080710/biomea-fusion-reports-second-quarter-2024-financial-results-and-corporate-highlights" target="_blank" rel="noreferrer noopener">fourth quarter of 2024</a>.
<h2 class="wp-block-heading">Biomea Fusion Stock Prediction For 2024</h2>
Equity research analysts on and off Wall Street typically use earnings growth and fundamental research as a form of valuation and forecasting. But many in trading turn to technical analysis as a way to form predictive models for share price trajectory.
Some investors look to trends to help forecast where they believe a stock could trade at a certain point in the future. Looking at Biomea Fusion, an investor could make an assessment about a stock's long term prospects using a moving average and trend line. If they believe a stock will remain above the moving average, which many believe is a bullish signal, they can extrapolate that trend into the future using a trend line. For Biomea Fusion, the 200-day moving average sits at $11.19, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, which is above the current price of $9.93. For more on charts and trend lines, <a href="https://pro.benzinga.com/">see a description here.</a>
Traders believe that when a stock is above its moving average, it is a generally bullish signal, and when it crosses below, it is a more negative signal. Investors could use trend lines to make an educated guess about where a stock could trade at a later date if conditions remain stable.
Price Action: BMEA stock is up 3.97% at $9.95 at the last check on Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/09/41069388/fda-approves-regeneronsanofis-blockbuster-dupixent-for-smokers-lung-disease" target="_blank" rel="noreferrer noopener">FDA Approves Regeneron/Sanofi&#8217;s Blockbuster Dupixent For Smoker&#8217;s Lung Disease</a>.</li>
</ul>

Biotech

Health Care

Movers

General

BMEA

FDA Removes Clinical Hold On Biomea Fusion's Early-Stage Trials For Potential Diabetes Candidate

WIIM

CEIX

CIVI

CTRA

EQNR

FANG

RCON

SHEL

VIST

Shares of energy companies are trading higher amid a rise in oil after the Israeli military carried out an airstrike on Hezbollah headquarters in Beirut, Lebanon. Also, Israeli Prime Minister Netanyahu, in a speech to the UN, mentioned Hezbollah and said his country has "every right to remove this threat and return our citizens to their homes safely."

- Teliso-V is an investigational antibody-drug conjugate (ADC) for patients with previously treated nonsquamous non-small cell lung cancer (NSCLC) with c-Met protein overexpression.
- Biologics License Application (BLA) submission for accelerated approval is supported by data from the Phase 2 LUMINOSITY trial (M14-239). Review of the BLA will be conducted under FDA's Oncology Center of Excellence (OCE) Real-Time Oncology Review (RTOR) program.&nbsp;
- There are currently no approved anti-cancer therapies specifically for c-Met overexpressing NSCLC and if approved Teliso-V would be the first-in-class therapy for this patient population.&nbsp;
NORTH CHICAGO, Ill., Sept. 27, 2024 /PRNewswire/ --&nbsp;AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) today announced submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for accelerated approval of telisotuzumab vedotin (Teliso-V) in adult patients with previously treated, locally advanced or metastatic epidermal growth factor receptor (EGFR) wild type, nonsquamous non-small cell lung cancer (NSCLC) with c-Met protein overexpression.
Approximately 85% of lung cancers are classified as NSCLC1&nbsp;and despite advances in treatment, lung cancer remains the leading cause of cancer-related deaths throughout the world.2&nbsp;The c-Met protein is a receptor tyrosine kinase found to be overexpressed in approximately 25% of advanced EGFR wild type, nonsquamous NSCLC patients3&nbsp;and is associated with a poor prognosis.4,5,6 Teliso-V is being evaluated within this patient population who currently have very limited treatment options.&nbsp;

ABBV

AbbVie Submits Biologics License Application To The FDA For Telisotuzumab Vedotin In Previously Treated Non-Small Cell Lung Cancer

Instead of lounging on a beach with a cocktail in hand, imagine checking into a <a href="https://www.benzinga.com/insights/options/24/08/40638929/wynn-resortss-options-frenzy-what-you-need-to-know">luxury resort</a> to inject your stem cells or heading to a high-tech clinic for a deep dive into your DNA.&nbsp;
Longevity tourism is the new frontier of travel. Here, the wealthy and influential are spending tens of thousands of dollars to unwind and attempt to <a href="https://www.benzinga.com/news/23/11/35634464/millionaire-biohacker-gets-outpaced-in-anti-aging-race-by-woman-spending-only-108-monthly-heres-her">slow down the aging process</a>.
Don't Miss:
<ul>
<li><a href="https://www.benzinga.com/money/are-you-rich">Are you rich?</a> Here&#8217;s what Americans think you need to be considered wealthy.</li>
<li>How do billionaires pay less in income tax than you?<a href="https://www.benzinga.com/money/tax-deferring-adv"> Tax deferring is their number one strategy</a>.</li>
<li>A billion-dollar investment strategy with minimums as low as $10 —<a href="https://www.benzinga.com/money/fundrise-flagship-fund"> you can become part of the next big real estate boom today.</a></li>
</ul>
Forget the usual spa days and yoga retreats. These days, wealthy travelers are booking trips that promise more than just relaxation – they want to add years to their lives. The options are almost endless. You can attend a $70,000 &#8220;five-day, five-star, deep dive into longevity&#8221; led by top researchers, go on a $44,000 stem-cell therapy stay or even sign up for a $20,000 blood-drawing retreat where they analyze over 200 biomarkers to create a personalized health plan.
Longevity tourism has exploded in popularity as more people want to stay active and healthy for as long as possible. It's a far cry from the old vacation model of all-you-can-eat buffets and too many piña coladas. Today, the wealthy seek ways to live better – and longer.
Trending: Founder of Personal Capital and ex-CEO of PayPal<a href="https://www.benzinga.com/money/evergreen-money"> re-engineers traditional banking with this new high-yield account — start saving better today.</a>
<h2 class="wp-block-heading">From Mediterranean Cruises to Longevity Cruises</h2>
Take Storylines, a cruise line that brands itself as a &#8220;blue zone at sea,&#8221; inspired by areas where people live the longest. Instead of just sunbathing and sipping drinks, passengers can get Botox, IV vitamin drips and bioidentical hormone therapy. And they aren't just eating any old cruise food; the world's healthiest diets inspire meals, all made with ingredients grown on the ship's solar-powered organic farm.
This new way of traveling isn&#8217;t limited to the open ocean. According to Fortune, upscale resorts are also participating. You may spend more than $44,000 on a four-part treatment package at the Four Seasons Resort in Maui, which includes <a href="https://www.benzinga.com/general/biotech/23/12/36215919/could-stemtech-be-the-next-herbalife-stem-cells-to-rejuvenate-the-body">stem cells and ozone therapy</a>. Alternatively, you can choose to detox after a night of excess with a 30-minute &#8220;Hangover IV&#8221; for a much lower $299.
Trending: These five entrepreneurs are worth $223 billion –<a href="https://www.benzinga.com/money/arrived-homes-private-credit-fund"> they all believe in one platform that offers a 7-9% target yield with monthly dividends</a>
Meanwhile, Canyon Ranch in Arizona has launched a four-day retreat called Longevity8. For $20,000, they'll draw your blood, run tests and give you a detailed health plan to follow. It's a hefty price tag for many people but for those who can afford it, it's surely an investment in their future.
These longevity-focused travels are quickly becoming the ultimate prestige symbol for the very wealthy. Nowadays, it matters more to live a long and healthy life than to possess the largest yacht or the priciest automobile.
Sure enough, this trend sounds over the top to many of us, but it makes sense for those who can afford it. After all, what's the point of being wealthy if you're not around to enjoy it for as long as possible?
Read Next:
<ul>
<li>If there was a new fund backed by Jeff Bezos offering a 7-9% target yield with monthly dividends<a href="https://www.benzinga.com/money/arrived-private-credit-fund"> would you invest in it</a>?</li>
<li>Can you guess how many retire with a $5,000,000 nest egg? &#8211;<a href="https://www.benzinga.com/money/retire-5mil-nest-egg"> How does it compare to the average?</a></li>
</ul>

Personal Finance

$70,000 Longevity School, $44,000 Stem-Cell Therapy Stay, $20,000 Blood Drawing Retreat – The New Travel Trend For The Rich And Powerful

U.S. stocks traded mixed midway through trading, with the Dow Jones index surging more than 250 points on Friday.
The Dow traded up 0.66% to 42,452.85 while the NASDAQ fell 0.45% to 18,108.42. The S&amp;P 500 also fell, dropping, 0.07% to 5,741.34.
Check This Out: <a href="https://www.benzinga.com/news/24/09/41065070/micron-to-150-here-are-10-top-analyst-forecasts-for-friday">Micron To $150? Here Are 10 Top Analyst Forecasts For Friday</a>
Leading and Lagging Sectors Energy shares jumped by 1.4% on Friday.
In trading on Friday, information technology shares fell by 0.3%.
Top Headline
According to government data released Friday, the Personal Consumption Expenditures (PCE) Price Index increased by 2.2% in August compared to the same period last year. The reading was below the 2.3% analysts were expecting and a drop from July's 2.5%.
The core PCE, which excludes volatile food and energy prices, was 2.7% year-over-year in August, matching analyst expectations and 0.1% higher than July's number.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>IonQ, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IONQ#NYSE">IONQ</a>) shares shot up 19% to $9.56 after the company announced it signed a $54.5 million contract with the United States Air Force Research Lab.</li>
<li>Shares of Onconetix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONCO#NASDAQ">ONCO</a>) got a boost, surging 64% to $5.57. Altos Venture reported a 32.5% stake in the company as of September 24 in a 13D filing on Thursday.</li>
<li>Biomea Fusion, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMEA#NASDAQ">BMEA</a>) shares were also up, gaining 11% to $10.59. Biomea Fusion disclosed that the FDA lifted its clinical hold on BMF-219 in Type 2 and Type 1 diabetes trials. Rodman &amp; Renshaw analyst Tony Butler upgraded Biomea Fusion from Neutral to Buy.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Seelos Therapeutics, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEEL#NASDAQ">SEEL</a>) shares dropped 12% to $4.39. Seelos announced postponement of its annual meeting of stockholders.</li>
<li>Shares of enVVeno Medical Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVNO#NASDAQ">NVNO</a>) were down 22% to $3.50 after the company announced the pricing of a $15 million public offering of 4.3 million shares at $3.50 per share.</li>
<li>Acadia Healthcare Company, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACHC#NASDAQ">ACHC</a>) was down, falling 25% to $56.60 after the company issued a statement stating they are cooperating fully with the authorities regarding a government investigation.</li>
</ul>
Commodities In commodity news, oil traded down 0.8% to $67.16 while gold traded down 0.3% at $2,686.90.
Silver traded up 0.1% to $32.355 on Friday, while copper fell 0.3% to $4.6245.
Euro zone
European shares were higher today. The eurozone's STOXX 600 gained 0.5%, Germany's DAX climbed 1.04% and France's CAC 40 jumped 0.49%. Spain's IBEX 35 Index rose 0.21%, while London's FTSE 100 rose 0.23%.
The industry confidence indicator in Spain climbed by 2.8 points from the prior month to a reading of -0.7 in September. Industrial producer prices in Italy declined by 0.8% year-over-year in August.
The economic sentiment indicator in the Eurozone slipped to 96.2 in September from 96.5 in August, while services sentiment indicator climbed to a four-month high level of 6.7 in September. The consumer confidence indicator in the Eurozone gained by 0.5 points to -12.9 in September.
Asia Pacific Markets
Asian markets closed mostly higher on Friday, with Japan's Nikkei 225 jumping 2.32%, Hong Kong's Hang Seng Index jumping 3.55%, China's Shanghai Composite Index gaining 2.88% and India's BSE Sensex falling 0.31%.
Hong Kong&#8217;s trade deficit widened to $33.1 billion in August versus $25.6 billion in the year-ago month. The People&#8217;s Bank of China slashed the reserve requirement ratio for banks by 50bps.
Economics
<ul>
<li>U.S. wholesale inventories increased 0.2% month-over-month to $905.7 billion in August compared to a revised 0.2% rise in the prior month.</li>
<li>The U.S. trade deficit in goods narrowed to $94.3 billion in August versus a revised $102.8 billion gap in the previous month.</li>
<li>U.S. personal income rose by 0.2% from the prior month to $24.015 trillion in August compared to a 0.3% gain in the previous month.</li>
<li>Personal spending rose by 0.2% month-over-month in August.</li>
<li>The US core PCE price index increased by 0.1% from the prior month in August compared to market estimates of a 0.2% increase and versus the 0.2% gain in the previous month. </li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/24/09/41064318/top-3-real-estate-stocks-that-are-preparing-to-pump-this-month">Top 3 Real Estate Stocks That Are Preparing To Pump This Month</a></li>
</ul>

Equities

Eurozone

Commodities

Intraday Update

Markets

Trading Ideas

ACHC

IONQ

NVNO

ONCO

SEEL

Nasdaq Moves Lower; Fed's Preferred Inflation Gauge Falls More Than Projected

On Friday, Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) released updated results from the investigational Phase&nbsp;1b&nbsp;RedirecTT-1 study evaluating the combination of Talvey&nbsp;(talquetamab) and Tecvayli&nbsp;(teclistamab) in patients with relapsed or <a target="_blank" href="https://www.benzinga.com/pressreleases/24/09/n41065095/novel-combination-of-talvey-talquetamab-tgvs-and-tecvayli-teclistamab-cqyv-suggests-high-response-" rel="noreferrer noopener">refractory multiple myeloma</a>.
At data cutoff, 44 patients had been treated with the recommended phase 2 regimen (RP2R) of 0.8 mg/kg of Talvey in combination with 3 mg/kg of Tecvayli every other week.
The overall response rate (ORR) was 79.5%, with a complete response or better (CR+) rate of 52.3%, an 18-month duration of response (DOR) of 85.9%, and an 18-month progression-free survival (PFS) rate of 69.8% with a median follow-up of 18.2 months.
Results from a subgroup analysis of patients with extramedullary disease demonstrated an ORR of 61.1%, with a CR+ rate of 33.3%, an 18-month DOR of 81.8%, and an 18-month PFS rate of 52.9% in patients with EMD at median follow-up 13.6 months.
Johnson &amp; Johnson&nbsp;also revealed updated results from the investigational Phase&nbsp;1b&nbsp;TRIMM-2 study evaluating the combination of Talvey with Darzalex&nbsp;Faspro and pomalidomide in patients with relapsed or refractory multiple myeloma that demonstrated <a target="_blank" href="https://www.benzinga.com/pressreleases/24/09/n41064961/talvey-talquetamab-tgvs-and-darzalex-faspro-daratumumab-and-hyaluronidase-fihj-based-combination-s" rel="noreferrer noopener">an ORR of 82%</a>.
At data cutoff, 77 patients had received Talvey&nbsp;in doses of 0.4 mg/kg weekly (QW) or 0.8 mg/kg biweekly (Q2W),&nbsp;with step-up doses&nbsp;combined with Darzalex&nbsp;Faspro and pomalidomide.
In the QW arm (n=18), the overall response rate (ORR) was 100%, with 56 percent having a complete response (CR) or better.
The Q2W arm (n=59) achieved 76% ORR, with 56% achieving CR or better.
The median duration of response (DOR) in the Q2W arm was 26.4 months, and the median progression-free survival (PFS) was 20.3 months.
Results showed that 52% of anti-CD38 refractory patients (n=64) achieved CR or better, and 70.8% received prior chimeric antigen receptor T cell therapy (n=24) achieved CR or better.
Patients who had received prior bispecific antibodies (n=29) achieved an 82.8% ORR.
Price Action: JNJ stock is trading 0.83% higher at $162.73 at the last check on Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/09/41066968/microsoft-google-meta-pave-path-to-ai-expansion-nvidia-and-broadcom-set-to-reap-benefits" target="_blank" rel="noreferrer noopener">Microsoft, Google, Meta Pave Path to AI Expansion, Nvidia and Broadcom Set to Reap Benefits</a>.</li>
</ul>
Photo via Shutterstock

Large Cap

Johnson & Johnson Reports Updated Data From Two Early-Stage Multiple Myeloma Studies Of Talvey Combo Treatment

Oil is trading higher after the Israeli military carried out an airstrike on Hezbollah headquarters in Beirut, Lebanon. Also, Israeli Prime Minister Netanyahu, in a speech to the UN, mentioned Hezbollah and said his country has "every right to remove this threat and return our citizens to their homes safely."

Legal

NYC Mayor Eric Adams Pleads Not Guilty To Federal Fraud Charges

Analyst Ratings

Live On CNBC, Brenda Vingiello Announces Bought Eaton, Boeing

The cannabis industry is facing increasing financial pressure as investors become more selective with their capital. With fewer opportunities for early-stage funding, companies are finding it harder to stand out and secure investment. As the market evolves, businesses must adapt and prove their long-term value.
<h3 class="wp-block-heading">Investor Priorities in Cannabis</h3>
Dai Truong, managing director at Arlington Capital Advisors and upcoming speaker at the <a href="https://www.benzinga.com/events/cannabis-conference/">Benzinga Cannabis Capital Conference</a> shared his perspective on the qualities currently attracting investor interest. According to Truong, only the top-performing companies are making the cut.
"The bar is still incredibly high, and investors are looking for companies that are market leaders in their segment, i.e., top 3 players or a chance to capture tremendous market share," Truong said. He explained that many cannabis investors are limited in available capital, making it essential for businesses to distinguish themselves as leaders.
See Also: <a href="https://www.benzinga.com/markets/cannabis/24/09/41070338/hemp-under-siege-state-bans-and-farm-bill-to-be-discussed-on-sept-30">Hemp Under Siege? State Bans And Farm Bill To Be Discussed On Sept. 30</a>
<h3 class="wp-block-heading">Looking Beyond Traditional Cannabis Investors</h3>
As the pool of cannabis-focused investors shrinks, Truong suggests that companies look beyond the usual funding sources. He points out that family offices, which are still exploring cannabis investments, present a promising opportunity for businesses seeking capital.
"Companies that are able to go outside of the obvious cannabis investors. For Family Offices that have yet to invest in Cannabis but are exploring) will have the best odds of raising capital in the near term," Truong said.
Truong also mentioned that businesses with substantial intellectual property or those that have expanded into other regulated industries, such as tech, are in a better position to attract investment. "For example, companies that have leading tech/IP that started in Cannabis but have expanded to other highly regulated industries are in an attractive position—where investors are actively chasing them," he explained.
<h3 class="wp-block-heading">Growing Interest from Other Industries</h3>
Another trend Truong highlighted is the growing overlap between the cannabis and beverage industries. Arlington Capital Advisors also works with beverage companies, and Truong noted that hemp beverage companies have been catching the attention of investors in that space, especially as regulations surrounding hemp evolve.
"This provides a new pool of investors that are still optimistic about the industry and do not have companies in their portfolio that have seen a valuation markdown," he said. Truong&#8217;s insights offer a clear picture of the challenges and opportunities in today's cannabis market as businesses look for new ways to secure funding and grow in an increasingly competitive environment.
Now Read: 
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/09/41067503/has-medical-marijuana-been-forgotten-in-cannabis-reform-its-therapeutic-benefits-are-critical">Has Medical Marijuana Been Forgotten In Cannabis Reform? &#8216;Its Therapeutic Benefits Are Critical&#8217;</a></li>
</ul>
Photo: Courtesy of Kindel Media via Pexels

Cannabis

Events

Exclusives

Interview

Cannabis Investors 'Actively Chasing' Companies Expanding Beyond The Industry Says Expert

Treasury Department Says U.S. Issues Fresh Iran Related Sanctions Over Interference In U.S. Election

SONM

Sonim Technologies Partners With Brodos AG To Expand Rugged Mobile Solutions In DACH Region

On Friday, Uber Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBER#NYSE">UBER</a>) announced it has partnered with Spirit Halloween to enhance<a target="_blank" href="https://www.benzinga.com/pressreleases/24/09/n41065750/uber-eats-partners-with-spirit-halloween-across-north-america" rel="noreferrer noopener"> its on-demand delivery services</a>.
The Spirit Halloween catalog will be accessible on Uber at the same in-store prices.
Uber One members will get a $0 delivery fee and a 5% discount on Spirit Halloween orders over $35. Additionally, all consumers can receive up to 40% off their next Spirit Halloween purchase of $50 or more through Halloween.
Beryl Sanders, Director of U.S. Grocery &amp; Retail partnerships at Uber said, "The holiday season officially kicks off this time of year, and households across the country are looking to on-demand delivery to get what's needed—now,"
"That's one of the reasons we're most excited to bring Spirit Halloween to Uber Eats and our other Uber apps to make costumes and other Halloween must-haves a cinch."
Also, Uber entered into a new $5 billion Credit Agreement with Bank of America, replacing its previous <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1543151/000155278124000539/e24397_uber-8k.htm" target="_blank" rel="noreferrer noopener">2015</a> agreement.
The unsecured revolving loans mature in 2029 and can be drawn in U.S. dollars or other currencies for general corporate purposes.
The loans offer interest options tied to either the term SOFR rate plus a 1% margin or a base rate with no margin.
The commitment fee starts at 0.125% annually, with interest rates and fees fluctuating based on Uber's debt ratings.
The agreement includes standard covenants and default conditions, requiring a minimum EBITDA-to-interest ratio of 3:1. At closing, $413 million in letters of credit were transitioned from the previous agreement, but no funds were borrowed.
Investors can gain exposure to the stock via iShares Trust iShares U.S. Transportation ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/IYT#BATS">IYT</a>) and&nbsp;Franklin Disruptive Commerce ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/BUYZ#BATS">BUYZ</a>).
Price Action: UBER shares are down 1.03% at $75.90 at the last check on Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/41028705/doordash-positioned-as-clear-market-share-gainer-with-growth-in-grocery-and-ads-ana" target="_blank" rel="noreferrer noopener">DoorDash Positioned As Clear Market Share Gainer With Growth In Grocery And Ads, Analyst Says, Upgrades Stock</a></li>
</ul>
Image Courtesy of Dutchmen Photography via Shutterstock

Financing

Contracts

Tech

BUYZ

iShares Dow Jones Transportation Average Index Fund

UBER

Uber Secures $5B Revolving Credit Facility, Also Teams Up With Spirit Halloween for Delivery

Tonix Pharmaceuticals Holding Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNXP#NASDAQ">TNXP</a>) shares are trading higher Friday after the company announced the United States Patent and Trademark Office&nbsp;granted a patent covering the subcutaneous delivery of Zembrace Symtouch for treating migraines.
The Details: Issued on September 24, the patent entitled &#8216;Pharmaceutical Composition for Treating Migraine&#8217; is anticipated to provide protection into 2036.
This comes after the company launched a campaign called &#8216;Does Your Migraine Pill Work Every Time?&#8217; with the goal of informing healthcare providers and consumers about the advantages of non-oral migraine medications.
How To Buy Tonix Pharmaceuticals Stock
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in Tonix Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNXP#NASDAQ">TNXP</a>)'s case, it is in the Health Care sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
See Also:<a href="https://www.benzinga.com/markets/cannabis/24/09/41033009/can-novo-nordisks-weight-loss-drug-ozempic-help-stem-the-devastating-addiction-crisis-new-resear"> Can Novo Nordisk&#8217;s Weight Loss Drug Ozempic Help Stem The Devastating Addiction Crisis? New Research Says Yes</a>
TNXP Price Action: At the time of writing, Tonix shares are trading 17.2% higher at 16 cents, according to data from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Image: Akava Photo from Pixabay

TNXP

What's Going On With Tonix Pharmaceuticals Stock Friday?

Constellation Energy (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ceg#NASDAQ">CEG</a>) has been amongst the hottest stocks in the market in 2024, with its shares up 125%. Those aren&#39;t the&nbsp;types of returns people usually associate with&nbsp;utility companies&nbsp;in such a short period of time. However, when a company is connected to the AI revolution, it&#39;s not so surprising. Most of this return has come just over the past week. Shares are up 26% since the company announced a blockbuster deal with a top tech firm.
Constellation Energy announced on Sept. 20 that it has entered into a 20-year agreement with Microsoft&nbsp;to supply the firm&#39;s data centers. The company plans to reopen the Three Mile Island nuclear facility and exclusively sell the generated electricity to Microsoft. This is a massive deal and deserves to be broken down further.
<h2>Three Mile Island Reopening Could Set a New Precedent</h2>
There are many interesting aspects of this deal. Most will first recall that in 1979, Three Mile Island was the site of the only nuclear meltdown in U.S. history. Although the accident did not directly cause any injuries or deaths, it hindered the progress of the nuclear industry for years.
However, it&#39;s important to note that the reactor scheduled for reopening is not the same one from 1979. That was Unit 2, while this nuclear deal involved Unit 1. Unit 1 continued to operate after the incident but was permanently shut down in 2019 at the discretion of Constellation due to issues with its profitability. However, the shutdown was not so permanent.
If the Nuclear Regulatory Commission (NRC) approves it, this deal could mark the first reopening of a shut-down nuclear site in the US. The Palisades Nuclear Plant in Michigan, owned by Holtec International, is another site under review for reopening. It&#39;s set to reopen in Oct. 2025.
However, the NRC will make its final decision on whether to renew its license on Jul. 31, 2025. Watching what happens will be an important indicator of the success of the Microsoft and Constellation deal. Overall, the lack of precedent alone creates some uncertainty.
However, government support for the Holtec deal adds optimism. The Biden-Harris administration is giving Holtec a $1.5 billion loan for the Palisades project. Michigan Governor Gretchen Whitmer has also expressed support.&nbsp;For Three Mile Island,&nbsp;57% of the residents in Harrisburg, PA, said they would support the reopening as long as they don&#39;t have to pay for it.
<h2>Constellation Wins on Price and Return on Investment</h2>
One reason this deal is even possible is that Unit 1 was being &quot;mothballed.&quot; This is the least immediate method for shutting down a nuclear site and leaves the option of reopening on the table. Fully decommissioning a site can take 15 to 20 years, so since it was shut down in 2019, it is still salvageable.
The most recent new nuclear project to begin commercial operation in the U.S. took nearly 15 years to complete. Its cost was over $30 billion for two reactors. This shows how massive a win this could be for Constellation. It only plans to spend $1.6 billion on the reopening and wants to have it operational by 2028.
Constellation is reportedly getting a sweet deal when it comes to the price of this energy. Analysts at Jefferies estimate that Microsoft will pay between $110 and $115 per megawatt-hour of electricity to Constellation. That&#39;s up to a 92% premium compared to the price for wind and solar energy in the same area. The distinction between wind and solar is important because hyperscalers like Microsoft want to fuel their data centers with renewable energy.
Jefferies expects the plant to generate $785 million in revenue by 2023. That estimate would let Constellation recoup its investment in just a few years and indicate a huge return on that investment over 20 years. When it comes to constellation&#39;s production capacity, the site&#39;s addition would be no small feat. Its 873 megawatts would increase Constellation&#39;s current 22-gigawatt nuclear capacity by around 4%.
<h2>Analysts Love the Deal</h2>
Overall, the deal feels like a home run for Constellation, and Wall Street analysts agree. At least nine analysts raised their price targets after the deal. The average target for those firms shows just a 6% upside for the stock, but it&#39;s hard to bet against what Constellation is bringing to the table. Morgan Stanley is most bullish, increasing their price target by $80. Their target implies an upside of 19%.
The article &quot;<a href="https://www.marketbeat.com/originals/constellation-energys-nuclear-deal-with-microsoft-is-a-home-run/">Constellation Energy&#39;s Nuclear Deal With Microsoft Is a Home Run</a>&quot; first appeared on MarketBeat.

Government

Regulations

Price Target

Constellation Energy's Nuclear Deal With Microsoft Is a Home Run

Live On CNBC, Kevin Simpson Announces Bought Meta

DA Davidson analyst Clark Wright maintains Zeta Global Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZETA#NYSE">ZETA</a>) with a Buy and maintains $35 price target.

ZETA

DA Davidson Maintains Buy on Zeta Global Holdings, Maintains $35 Price Target

Roth MKM analyst Matt Koranda maintains AMMO (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POWW#NASDAQ">POWW</a>) with a Neutral and lowers the price target from $1.6 to $1.5.

POWW

Roth MKM Maintains Neutral on AMMO, Lowers Price Target to $1.5

DA Davidson analyst Gil Luria maintains Microsoft (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) with a Neutral and maintains $475 price target.

MSFT

DA Davidson Maintains Neutral on Microsoft, Maintains $475 Price Target

Wells Fargo analyst Mohit Bansal maintained a Hold rating on Travere Therapeutics (TVTX – Research Report) on September 6. The company's shares clo...

Travere Therapeutics (TVTX) Gets a Hold from Wells Fargo

Travere Therapeutics (TVTX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ed Arce from H....

Buy Rating Affirmed for Travere Therapeutics Amid Proactive HARMONY Study Management and Strong Financial Stance

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Entera Bio (ENTX – Research Report), Legend Biotech ...

Analysts Are Bullish on These Healthcare Stocks: Entera Bio (ENTX), Legend Biotech (LEGN)

Travere slips after pausing late-stage trial's enrollments

TD Cowen analyst Tyler Van Buren maintained a Buy rating on Travere Therapeutics (TVTX – Research Report) today and set a price target of $15.00. T...

TD Cowen Sticks to Its Buy Rating for Travere Therapeutics (TVTX)

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Adverum Biotechnologies (ADVM – Research Report), Bi...

Analysts Offer Insights on Healthcare Companies: Adverum Biotechnologies (ADVM), Biomea Fusion (BMEA) and Travere Therapeutics (TVTX)

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on DENTSPLY SIRONA (XRAY – Research Report) and Travere...

Analysts Offer Insights on Healthcare Companies: DENTSPLY SIRONA (XRAY) and Travere Therapeutics (TVTX)

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Curis (CRIS – Research Report), Scholar Rock Holding...

Analysts Offer Insights on Healthcare Companies: Curis (CRIS), Scholar Rock Holding (SRRK) and Travere Therapeutics (TVTX)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Travere Therapeutics (TVTX – Research Report) and Elanco Animal H...

Analysts Offer Insights on Healthcare Companies: Travere Therapeutics (TVTX) and Elanco Animal Health (ELAN)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Lexicon Pharmaceuticals (LXRX – Research Report) and Travere Ther...

Analysts Offer Insights on Healthcare Companies: Lexicon Pharmaceuticals (LXRX) and Travere Therapeutics (TVTX)

ADVM

CRIS

ELAN

ENTX

LEGN

LXRX

SRRK

TVTX

XRAY

Press Releases

Travere Therapeutics to Report Second Quarter 2024 Financial Results

Earnings

Travere Therapeutics Reports Second Quarter 2024 Financial Results

Ligand Reports Second Quarter 2024 Financial Results

Travere Therapeutics to Present at Upcoming Investor Conferences

Travere Therapeutics to Present Abstracts at the Society for the Study of Inborn Errors of Metabolism Annual Symposium 2024

Travere Therapeutics Announces Full FDA Approval of FILSPARI® (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy

Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy

Travere Therapeutics to Present at the 2024 Cantor Global Healthcare Conference

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Travere Therapeutics Announces Voluntary Pause of Enrollment in the Phase 3 HARMONY Study of Pegtibatinase Related to Commercial Manufacturing Scale-Up

Comments

Travere Therapeutics

Vendite allo scoperto

Travere Therapeutics (NASDAQ:TVTX) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO